- Home
- ALXO
as of 12-05-2025 1:55pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 79.7M | IPO Year: | 2020 |
| Target Price: | $3.30 | AVG Volume (30 days): | 350.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $2.27 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ALXO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$1.08
Shares
71,163
Total Value
$76,891.62
Owned After
305,121
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$1.07
Shares
21,070
Total Value
$22,460.62
Owned After
305,121
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Sep 17, 2025 | Buy | $1.08 | 71,163 | $76,891.62 | 305,121 | |
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Sep 16, 2025 | Buy | $1.07 | 21,070 | $22,460.62 | 305,121 |
Compare ALXO vs Leading Stocks
See how ALXO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.